文献速递食管与纵隔外科

局部晚期食管癌新辅助治疗应依据肿瘤组织学类型选择

Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
PubMed 文献 · Ann Thorac Surg · 2018-09-29

该研究回顾1989至2016年间700例接受新辅助化疗或放化疗后手术的食管癌患者,比较不同组织学类型下的生存结局。腺癌患者中放化疗提高病理缓解率但5年生存无差异;鳞癌患者中放化疗改善5年癌症特异性生存。提示新辅助方案应依据组织学类型制定。

要点

  • 腺癌:放化疗提高病理完全缓解率,但5年生存与单纯化疗无差异。
  • 鳞癌:放化疗较单纯化疗改善5年癌症特异性生存(87% vs 68%)。
  • 局部晚期食管癌新辅助方案应依据肿瘤组织学类型选择。

核心结论

  • 腺癌患者新辅助放化疗较单纯化疗提高局部肿瘤反应但生存无差异。
  • 鳞癌患者新辅助放化疗较单纯化疗改善癌症特异性生存。
  • 局部晚期食管癌新辅助方案应依据肿瘤组织学类型制定。

研究设计与样本

  • 回顾性分析前瞻性收集的1989至2016年食管癌患者数据库。
  • 共700例患者接受新辅助放化疗(n=112)或新辅助化疗(n=226)后手术。
  • 采用Kaplan-Meier log-rank检验比较无病生存和癌症特异性生存,Cox回归分析独立预测因素。

主要发现

  • 鳞癌患者更常接受新辅助放化疗(49% vs 26%,p<0.001)。
  • 腺癌患者中放化疗组临床完全缓解率18% vs 7.4%,病理阴性淋巴结52% vs 30%(p=0.001),病理完全缓解21% vs 5.1%(p<0.001)。
  • 腺癌患者5年无病生存(28% vs 31%,p=0.636)和癌症特异性生存(51% vs 52%,p=0.824)无差异。
  • 鳞癌患者放化疗组病理阴性淋巴结65% vs 46%(p=0.064),病理完全缓解42% vs 12%(p<0.05)。
  • 鳞癌患者5年癌症特异性生存放化疗组优于化疗组(87% vs 68%,p=0.019)。

临床怎么用

  • 鳞癌患者优先考虑新辅助放化疗以改善癌症特异性生存。
  • 腺癌患者新辅助放化疗与化疗生存相当,需结合病理缓解和毒性权衡选择。

局限性

  • 回顾性研究,治疗选择由多学科团队决定,存在选择偏倚。
  • 鳞癌亚组样本量较小(n=98)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Controversy exists over the optimal neoadjuvant therapy in patients with locally advanced esophageal cancer (EC). Although most groups favor neoadjuvant chemoradiation (nCRT), some prefer preoperative chemotherapy (nCT) without radiation. The objective of this study was to compare outcomes in EC patients undergoing either regimen, followed by surgery. METHODS: We reviewed a prospectively collected database of EC patients undergoing esophagectomy after nCT or nCRT from 1989 to 2016. Choice of therapy was at the discretion of the multidisciplinary team. Disease-free survival (DFS) and cancer-specific survival (CSS) were compared by the Kaplan-Meier log-rank test. Independent predictors of CSS were estimated by Cox regression analysis. RESULTS: Among 700 EC patients 338 patients were treated with nCRT (n = 112) or nCT (n = 226) followed by surgery. Patients were well matched for age, gender, and clinical stage, although patients with squamous cell carcinoma were more likely to receive nCRT (49% vs 26%, p < 0.001). At surgery 90% and 91% of nCRT and nCT patients, respectively, underwent transthoracic esophagectomy. nCRT, in comparison with nCT, was associated with similar rates of Calvien-Dindo grade III/IV complications (34% vs 33%, p = 0.423) but with a trend toward higher perioperative mortality (5% vs 1%, p = 0.064). Among adenocarcinoma patients (n = 239) the use of nCRT was associated with higher rates of complete clinical response (18% vs 7.4%), pathologically negative lymph nodes (52% vs 30%, p = 0.001), and complete pathologic response (21% vs 5.1%, p < 0.001). However, there was no difference between nCRT and nCT for 5-year DFS (28% vs 31%, p = 0.636) or CSS (51% vs 52%, p = 0.824) among adenocarcinoma patients. For patients with squamous cell carcinoma (n = 98), nCRT and nCT had similar rates of complete clinical response (31% vs 26%, p = 0.205), but the rates of negative nodes (65% vs 46%, p = 0.064) and of complete pathologic response (42% vs 12%, p < 0.05) were higher with nCRT. For these patients nCRT was associated with no statistical difference in 5-year DFS (57% vs 40%, p = 0.595) but with improved 5-year CSS (87% vs 68%, p = 0.019) compared with nCT. On multivariable analysis for CSS, nCRT predicted improved survival for patients with squamous cell carcinoma (hazard ratio, 0.242; 95% confidence interval, 0.071-0.830) but not for those with adenocarcinoma (univariate hazard ratio, 0.940; 95% confidence interval, 0.544-1.623). CONCLUSIONS: For adenocarcinoma patients undergoing surgery for EC, nCRT leads to increased local tumor response compared with nCT alone but with no difference in survival. For squamous carcinoma patients nCRT appears to improve CSS compared with nCT. For patients with locally advanced EC targeted neoadjuvant regimens should be used depending on tumor histology.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Stiles BM, Kamel MK, Harrison SW, et al. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology. Ann Thorac Surg. 2018. PMID: 30278165. doi:10.1016/j.athoracsur.2018.07.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。